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In rodent models of type 2 diabetes (T2D), sustained remission of hyperglycemia can be
induced by a single intracerebroventricular (icv) injection of fibroblast growth factor 1 (FGF1),
and the mediobasal hypothalamus (MBH) was recently implicated as the brain area
responsible for this effect. To better understand the cellular response to FGF1 in the MBH, we
sequenced >79,000 single-cell transcriptomes from the hypothalamus of diabetic Lepob/ob
mice obtained on Days 1 and 5 after icv injection of either FGF1 or vehicle. A wide range of
transcriptional responses to FGF1 was observed across diverse hypothalamic cell types, with
glial cell types responding much more robustly than neurons at both time points. Tanycytes
and ependymal cells were the most FGF1-responsive cell type at Day 1, but astrocytes and
oligodendrocyte lineage cells subsequently became more responsive. Based on histochemical
and ultrastructural evidence of enhanced cell-cell interactions between astrocytes and Agrp
neurons (key components of the melanocortin system), we performed a series of studies
showing that intact melanocortin signaling is required for the sustained antidiabetic action of
FGF1. These data collectively suggest that hypothalamic glial cells are leading targets for the
effects of FGF1 and that sustained diabetes remission is dependent on intact melanocortin
signaling.
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Type 2 diabetes (T2D) is among the most common andcostly biomedical challenges confronting modern society1.Standard treatment of this disease involves daily dosing of
one or more antidiabetic drugs and can be effective but fails to
deliver adequate glycemic control to a majority of patients2. A
compelling need for more effective treatment modalities therefore
exists, and the brain has emerged as an important target for
research in this area3.
We recently reported that, in Lepob/ob mice and other rodent
models of T2D, sustained diabetes remission can be achieved by a
single intracerebroventricular (icv) injection of fibroblast growth
factor 1 (FGF1)4, and the hypothalamus has been identified as the
brain area responsible for this FGF1 effect5. While this finding is
in line with accumulating evidence supporting a key role for the
hypothalamus in glucose homeostasis, our current understanding
of glucoregulatory neurocircuitry is limited6,7. Most of this work
is focused on hypothalamic neurons with glucose-sensing prop-
erties8, but many glial cell types are also potential targets for the
hypothalamic action of FGF1, since tanycytes and astrocytes are
implicated in glucose homeostasis9,10 and since glial cell
responsiveness to FGF ligands is well documented5,11,12. More-
over, glia–neuron interactions can modify neuronal activity and
remodel neurocircuit structure13–15, effects of interest for
understanding the long-lived nature of the FGF1 effect.
As an unbiased approach to measuring gene expression within
single cells in the hypothalamus16–18, single-cell RNA sequencing
(scRNA-seq) provides a useful strategy both for identifying FGF1-
responsive cell types in this brain area and for characterizing their
response to icv FGF1 administration at the transcriptional level.
With this goal in mind, we performed this analysis across several
time points following a single icv injection of FGF1 or vehicle in
diabetic Lepob/ob mice. Using a combination of scRNA-seq and
histological techniques, we report that glial responses to FGF1
were generally rapid in onset and accompanied by an activated
morphology. We also identified Agrp neurons, key components
of the melanocortin signaling pathway, as the most FGF1-
responsive neuronal cell type at the transcriptional level, and in a
series of in vivo studies, we show that sustained diabetes remis-
sion induced by icv FGF1 is dependent on intact melanocortin
receptor signaling.
Results
Study design. Consistent with previous studies4,5,11, icv delivery
of FGF1 (3 µg) into the lateral ventricle of diabetic Lepob/ob
mice induced a robust but transient anorectic response at Day 1,
with normalization of blood glucose (BG) levels occurring by Day
5 (Fig. 1a). To identify transcriptional correlates of these distinct
responses to FGF1, we generated a series of RNA-seq datasets at
Days 1, 5, and 42 (Fig. 1a) and adjusted for differences of food
intake by pair-feeding of icv vehicle-injected controls to the
intake of icv FGF1-injected mice.
To transcriptionally characterize Days 1 and 5, we performed
single-nucleus RNA-sequencing (snRNA-seq) and generated a
dataset comprising 15,291 cells that clustered into 9 overall cell
populations (Fig. 1b, c). For this dataset, we, on average,
recovered 3258 transcripts (unique molecular identifiers (UMIs))
and 1,792 unique genes per cell across all hypothalamic cell
populations.
Tanycytes, ependymal, and astrocytes are highly responsive to
icv FGF1. To better characterize the response of hypothalamic
tanycytes, astrocytes, and other glial cells Day 1 after icv FGF1
injection in diabetic Lepob/ob mice, we extracted all non-neuronal
cells and re-clustered them to delineate glial subpopulations
(Fig. 1d). To estimate which subpopulations were most affected
one day after icv FGF1 injection, differentially expressed genes
(DEGs) were identified with a repeated downsampling approach
to control for both cell number and between-sample variation19.
In line with previous evidence that both tanycytes and astrocytes
are highly responsive to FGF14,5,11, robust transcriptomic
responses were observed in tanycytes, ependymal cells, and, to a
lesser degree, astrocytes (false discovery rate (FDR) < 0.1; Fig. 1e).
Using a pseudobulk approach to identify DEGs (see “Methods”),
our analysis of FGF1-induced transcriptional changes identified a
core set of genes (n= 21) shared between tanycytes, ependymal
cells, and astrocytes, suggesting a common response across these
cell types (Fig. 1f, Supplementary Data 1). Furthermore, we tested
for enrichment of genesets in the Gene Ontology biological
process (GO:BP)20, REACTOME (REAC)21, and Kyoto Ency-
clopedia of Genes and Genomes (KEGG)22 databases (Fig. 1g;
Supplementary Data 2). Tanycytes and ependymal cells showed
strong upregulation of ribosomal pathways and downregulation
of cilia activity, whereas astrocytes showed increased activity in
processes involved in tissue remodeling compared to pair-fed,
vehicle-treated mice.
To further characterize both the biological pathways induced
by FGF1 across tanycytes, ependymal cells, and astrocytes and
how these responses change over time, we performed weighted
gene co-expression network analysis (WGCNA)23 on these glial
subsets. Of the nine modules identified, three were significantly
increased by icv FGF1 at Day 1 (Fig. 1h). Modules sn-glia-M1 and
sn-glia-M2 were increased by FGF1 to a similar extent across all
three cell types, whereas sn-glia-M3 appeared to be more strongly
upregulated in tanycytes than the other cell types (Fig. 1h; linear
mixed-effects models; FDR < 0.05; Supplementary Data 3). Con-
sistent with the ability of FGF1 to signal through the extracellular
signal-related kinase 1/2 (ERK1/2) pathway5, the sn-glia-M1
module was significantly enriched for “mitogen-activated protein
kinase (MAPK) cascade” and “FGF receptor 1 signaling” path-
ways and included the gene Itgav encoding an integrin subunit
shown to modulate FGF signaling24. Furthermore, module sn-
glia-M2, which included Gfap and Vim (markers of reactive
astrocytes25), was upregulated across all three cell populations
(Fig. 1h), suggesting a pan-reactive glial response. Module sn-glia-
M3 was strongly induced in tanycytes and contains the gene
Sprr1a (Fig. 1i), which marks a unique subset of tanycytes
situated at the junction of the arcuate nucleus (ARC) and the
median eminence (ME)16.
Whereas these three modules were strongly induced Day 1
after icv FGF1 injection, each of these responses was nearly
normalized by Day 5, with a different set of modules showing
increased expression relative to vehicle at this time point. Among
the modules upregulated Day 5 were sn-glia-M4 and sn-glia-M5,
which were activated specifically in astrocytes and ependymal
cells, respectively (Fig. 1h). These data suggest that the
transcriptomic response to FGF1 evolves over time in a manner
that differs fundamentally between astrocyte, tanycyte, and
ependymal cell populations.
Tanycyte activation is sustained through Day 5 following icv
FGF1 injection. As tanycyte and ependymal cell responses
diverged with the passage of time following icv FGF1 injection,
we generated a larger single-cell RNA-sequencing (scRNA-seq)
Day 5 dataset, which comprised 63,904 hypothalamic cells from a
separate cohort of icv FGF1-injected Lepob/ob mice and PF, icv
vehicle-injected controls (n= 6/group). After quality control and
doublet removal, cells were clustered into 14 cell populations
(Supplementary Fig. 1). On average, we recovered 1802 UMIs and
966 unique genes/cell across all cell populations. Within this
larger dataset, we first inspected cell types lining the third
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Fig. 1 Study design and icv FGF1-induced temporal glia responses. a Diabetic Lepob/ob mice received a single intracerebroventricular (icv) injection of
FGF1 (3 µg) or vehicle at Day 0. Hypothalami were harvested on Days 1, 5, and 42 after icv injection. Vehicle-injected mice were pair-fed (PF) to the
amount of food consumed by icv FGF1-injected Lepob/ob mice and morning blood glucose levels were monitored. Plots are represented as mean ± SEM, and
source data are provided as a Source data file; FGF1 (n= 17), vehicle (n= 15). b Uniform manifold approximation and projection (UMAP) clustering of
hypothalamic nuclei from Day 1 and Day 5 snRNA-seq datasets. Source data are available through the NCBI Gene Expression Omnibus (GEO; GSE153551).
c UMAP clustering from b colored according to treatment group and time of euthanasia. d UMAP clustering of hypothalamic non-neuronal cells from Day 1
and Day 5 snRNA-seq datasets. e Number of differentially expressed genes (DEGs) for non-neuronal subclusters at Day 1 identified through repeated
downsampling (10 cells/group/cell type/iteration; 100 iterations), n= 3 mice/group. Data are presented as median with interquartile range (IQR) and
summary statistics are provided as a Source data file. f Each bar represents the number of unique DEGs for one or a certain combination of cell types
(pseudobulk approach, see “Methods”) from Day 1 snRNA-seq dataset, n= 3 mice/group. g Associated Gene Ontology terms (biological process category;
red), KEGG (blue) and REACTOME (green) pathways associated with DEGs in the indicated cell types. Point size indicates −log10(p value) (Bonferroni
adjusted). h Weighted gene co-expression network analysis (WGCNA) of tanycytes, ependymal cells, and astrocytes from Days 1 and 5 snRNA-seq
datasets. Significantly changed gene modules (linear mixed-effects model; FDR < 0.05) are indicated with color and cell-specific expression is indicated by
shape. Modules are plotted according to their β-values; Day 1 (n= 3/group), Day 5 (n= 2/group). i Module plots of top 15 genes of sn-glia-M1–sn-glia-M3,
which are upregulated on Day 1. Genes in red denote genes mentioned in the text. Astro astrocytes, Tany tanycytes, Epend ependymal cells, Olig
oligodendrocytes, OPC oligodendrocyte precursor cell, COP committed to differentiate oligodendrocyte, VLMC vascular leptomeningeal cell.
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ventricle (3V) (Supplementary Fig. 2). Subclustering identified the
four major tanycyte subpopulations: α1-, α2-, β1-, and β2-
tanycytes (Fig. 2a). Because tanycyte cell identity and function
vary with dorsal–ventral distribution along the ventricular wall,
we anticipated finding a continuum of gene expression moving
dorsally up the 3V. We therefore plotted all tanycyte cells in
principal component (PC) space, which revealed a one-
dimensional curve, reminiscent of what is seen in terminally
differentiated cells with spatial zonation26. We next fit a principal
curve to our data and assigned each cell a value on that curve,
henceforth referred to as “pseudoventricle score” (Fig. 2b).
Application of WGCNA across this tanycyte population identi-
fied 35 modules (Supplementary Data 5), of which 7 showed a
significant difference following icv FGF1 treatment compared to
vehicle across at least 5 consecutive points along the pseudo-
ventricle. Module sc-tany-M1 showed a strong significant (linear
mixed-effects model; FDR < 0.05) increase in expression exclud-























































































































Fig. 2 Tanycyte module expression maps to the spatial distribution lining the third ventricle. a UMAP clustering of tanycytes (β2-, β1-, α1-, α2-
Tanycytes) from the Day 5 single-cell RNA-sequencing (scRNA-seq) dataset. Cell type annotations were inferred from a published dataset16. b Tanycyte
lineage cells plotted on principal components 1 and 2 revealed a trajectory (left). The colors represent the subtype of each cell from a. A principal curve fit
across the trajectory was used to assign a pseudoventricle score to each cell corresponding to the spatial location of that cell type along third ventricular
(3V) wall. Density plot of each tanycyte subpopulation plotted along the pseudoventricle revealed a continuum of gene expression and non-distinct shifts
in the expression of marker genes along the pseudoventricle. c Scaled module expression of sc-tany-M1 in FGF1-treated (black) and vehicle (gray) tanycytes
(linear mixed-effects model; bin size of 1; mean ± SEM; *p < 0.05) (Bonferroni adjusted) from the Day 5 scRNA-seq dataset (n= 6 mice/group). Exact
adjusted p values are provided in Supplementary Data 5. ME module eigengene. d Gene–gene network plot of the correlation of top 15 genes in module sc-
tany-M1 (left) and associated pathways (right). Genes mentioned in the text are labeled in red. e Representative images of immunolabeling of vimentin in
diabetic Lepob/ob mice 1 week after vehicle or icv FGF1 injection. Pixel dimensions: 0.27 × 0.27 × 2.00microns. Quantification: dots represent volume of
vimentin-positive voxels assessed by iMARIS for individual animals (mean from 2 sections per animal, n= 4/group), mean ± SEM. Unpaired t test, two
tailed, *p= 0.022 (not adjusted). Source data are provided as a Source data file. f Scaled module expression of sc-tany-M2, sc-tany-M3, sc-tany-M5, sc-tany-
M6, and sc-tany-M23 with 5 consecutive points of difference in expression along the pseudoventricle between FGF1-treated (black) and vehicle (gray)
tanycytes (linear mixed-effects models; bin size of 1; mean ± SEM; *p < 0.05) (Bonferroni adjusted) from the Day 5 scRNA-seq dataset (n= 6 mice/group).
Exact adjusted p values are provided in Supplementary Data 5.
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high. This module contained the gene Vim and enriched for
pathways such as “glycolysis” and “gluconeogenesis” (Fig. 2c, d),
suggesting a shift in metabolic processes in these cells. Immu-
nostaining for vimentin confirmed a robust increase in both
ependymal and tanycyte vimentin content 1 week after icv FGF1
injection at the predicted ventricle heights. Combined with a
marked increase in the number of tanycyte processes projecting
into adjacent hypothalamic parenchyma, these findings are highly
suggestive of a phenotype switch in these cells (Fig. 2e). Fur-
thermore, we found that sc-tany-M2, which contained genes with
stem cell-like properties27,28, was increased specifically in the
ventral part of the pseudoventricle, and sc-tany-M3 exhibited a
significant FGF1-induced increase in expression across nearly the
entire pseudoventricle and comprised genes involved in protein
synthesis thus mirroring the response of tanycytes on Day 1.
Modules sc-tany-M5 and sc-tany-M6 were expressed dorsally
along the pseudoventricle, included Cd24a and Igfbp5, respec-
tively, confirmed by in situ hybridization in cells lining the 3V
(Supplementary Fig. 3)29, and identified in progenitor cells in the
ventricular–subventricular zone30. Genes of the peroxiredoxin
family characteristic of sc-tany-M23 exhibited a distinct expres-
sion pattern characteristic of α2-tanycytes, suggesting a role for
this tanycyte subset in the hypothalamic response to oxidative
stress that is upregulated by FGF1 (Fig. 2f). Additional studies are
warranted to determine the contribution made by various tany-
cyte subsets to FGF1-induced diabetes remission (for more
detailed results and a full list of tanycyte and ependymal modules,
please refer to Supplementary Notes, Supplementary Fig. 4, and
Supplementary Data 4 and 5).
Evolution of the astrocyte response to icv FGF1. In response to
various stimuli, the astrocyte phenotype can change rapidly and
dramatically13. To date, neurotoxic, neuroprotective, pan-reac-
tive, neuron-interactive, and neuronal activity-induced astrocyte
phenotypes have been reported25,31. To test whether astrocyte
responses on Day 1 or Day 5 after icv FGF1 treatment correspond
to any of these phenotypes, we first performed WGCNA on
astrocytes in the snRNA-seq dataset. Of the 7 identified modules,
3 were significantly increased on Day 1 (sn-astro-M1–sn-astro-
M3) and 1 module was significantly increased on Day 5 (sn-astro-
M4; Fig. 3a; linear mixed-effects models; FDR < 0.05; Supple-
mentary Data 6). The 3 upregulated astrocyte modules on Day 1
enriched for markers of pan-reactive astrocytes, while sn-astro-
M2 and sn-astro-M3 also enriched for markers of neuroprotective
astrocytes (Fig. 3a). Although sn-astro-M1 did not enrich for
markers of either neurotoxic or neuroprotective astrocytes, its
hub gene Npas3 (Fig. 3b) is a transcription factor belonging to the
bHLH-PAS superfamily known to be involved in FGF signaling,
hypoxia, circadian rhythm, and metabolic pathways and has been
proposed as a link between mental illness and metabolic
disorders32.
In contrast, sn-astro-M4, which was upregulated on Day 5 post-
FGF1 treatment, significantly enriched for neuron-interacting
(NeurI) genes, suggestive of increased astrocyte–neuronal inter-
action. Among hub genes for sn-astro-M4 was Sparcl1, a
matricellular protein implicated in synaptic plasticity33, as well
as genes encoding proteins involved in synaptic glutamate (Ndrg2)
and potassium (Kcnj10) homeostasis (Fig. 3b). This module
enriched for the terms “ammonium ion metabolic process,”
“PPAR signaling pathway,” and “lipid metabolic process”
(Supplementary Data 6), consistent with a model in which
FGF1 helps to reduce neuronal stress34 through increased
neuron–astrocyte metabolic coupling.
To confirm the snRNA-seq findings on Day 5 post-treatment
and to gain more insight in the glial response to icv FGF1, we
again utilized the larger scRNA-seq dataset. The relatively high
number of resampled DEGs in astrocytes at Day 5 compared to
the other cell glial cell types confirmed that, in these cells, the
transcriptional response at Day 5 was more robust than at Day 1
(Fig. 3c). Pseudobulk analysis of astrocytes identified 186 DEGs
on Day 5 (|log2 fold change (FC)| > 1; FDR < 0.05), of which 94
were upregulated and 92 downregulated, with Gfap, Aqp4, and
Vim among the top upregulated genes (Fig. 3d; Supplementary
Data 7). Using WGCNA, we identified 6 distinct astrocyte
modules associated with FGF1 treatment on Day 5 (linear mixed-
effects models; beta > 0.005; FDR < 0.05) (sc-astro-M1–sc-astro-
M6; Fig. 3e; Supplementary Data 8), 3 of which were upregulated
by icv FGF1. Hypergeometric enrichment revealed a significant
overlap between sn-astro-M4 and sc-astro-M1 (10 genes in
common) as well as with sc-astro-M3 (7 genes in common;
Fig. 3e). Module sc-astro-M3 included genes involved in
regulating homeostasis of both synaptic glutamate (Slc1a2,
Slc1a3) and GABA (Slc6a11), as well as the major astrocyte
water channel Aqp4 (Fig. 3f). Module sc-astro-M1 included genes
regulating synapse formation (Sparcl1, Sparc), dendritic growth
(Psap), and other neuroprotective functions (Cpe, Clu, Plat).
These findings confirm the astrocyte response on Day 5 and are
suggestive of multiple neuroprotective responses that range from
changes in interstitial fluid homeostasis to direct regulation of
synapse/dendrite formation (Supplementary Data 8).
To validate and extend these transcriptomic findings, we used
immunohistochemistry (IHC) to determine whether expression of
Aqp4 (a shared upregulated gene at Day 5 in all astrocyte analyses
and datasets) was increased at the protein level in astrocytes. We
found that, in a separate cohort of diabetic Lepob/ob mice, Aqp4
protein content was increased 1 week after icv FGF1 injection,
particularly in the mediobasal hypothalamus (MBH; Fig. 3g). We
also detected a robust increase of glial fibrillary acidic protein
(GFAP; encoded by Gfap) immunostaining in astrocytes 1 week
following icv FGF1 injection, confirming the FGF1-induced
astrocyte modules sc-astro-M3 and sn-astro-M2 containing Gfap.
Combined with the robust, star-shaped astrocyte morphological
change induced by FGF1 (Fig. 3g), these findings are suggestive of
an astrocyte phenotype switch. Clarification of contribution made
by these astrocyte responses to FGF1-induced glucose lowering is
warranted.
Unique temporal signatures in oligodendrocytes induced by icv
FGF1. At a transcriptional level, oligodendrocytes displayed a
distinct temporal response to FGF1. While evidence of minor
immune activation was seen in mature oligodendrocytes on Day 1
(Supplementary Data 3), icv FGF1 had minimal effects on oli-
godendrocyte precursor cells (OPCs) at this early time point. By
Day 5, however, our resampling test indicated a strong response
in both oligodendrocytes and committed to differentiate oligo-
dendrocyte precursors (COPs) (Fig. 3c). To better understand
these responses, we extracted all oligodendrocyte lineage cells
from our scRNA-seq dataset and mapped them to an existing
dataset with a more detailed annotation of transcriptional oligo-
dendrocyte heterogeneity35 (Fig. 4a). Retaining only cells that
mapped with high confidence between datasets, we detected a
significant increase in populations of both COPs and newly
formed oligodendrocytes (NFOLs) in FGF1-treated mice (Fig. 4b)
but not in mature oligodendrocytes.
We next used Monocle236 to sort these cells along their likely
developmental trajectories. The pseudotime trajectory confirmed
the effect of icv FGF1 to increase the pool of cells at an
intermediate pseudotime (Fig. 4c), corresponding to an accumu-
lation of cells differentiating from OPCs toward mature
oligodendrocytes. Using RNAScope to detect Gpr17 expression
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as a proxy for COPs and NFOLs (Fig. 4d) in a separate cohort of
Lepob/ob mice, we confirmed an increase in the number of these
oligodendrocyte lineage cells in the ARC of icv FGF1-injected
mice compared to vehicle-treated, PF controls (Fig. 4e), a
response that appeared to extend beyond the MBH. Together,
these results suggest that oligodendrocyte differentiation was
induced by icv FGF1 in the hypothalamus of diabetic Lepob/ob
mice. Although oligodendrocytes are well known to ensheath
axons and provide metabolic support, and although glucose has
been shown to be rapidly metabolized by oligodendrocytes37, we
are unaware of evidence implicating oligodendrocyte lineage cells
in the control of glucose homeostasis. Whether and how these
cells might contribute to sustained FGF1-induced diabetes
remission warrants additional study.
Effect of FGF1 on neurons. To confidently identify established
hypothalamic neuronal subtypes in diabetic Lepob/ob mice, we
propagated labels from published hypothalamic single-cell data-
sets16–18 (see “Methods”) and subclustered all confidently map-
ped cells into 15 hypothalamic neuron-specific cell populations




























































































































































































































Fig. 3 Evolution of the astrocyte response to icv FGF1. a Identification of sn-astro-M1–sn-astro-M3 upregulated at Day 1 and sn-astro-M4 upregulated at
Day 5 in FGF1-treated mice (linear mixed-effects model, FDR < 0.05) using WGCNA on astrocytes from the snRNA-seq datasets. Enrichment of DEGs in
astrocytes in response to lipopolysaccharide (neurotoxic, A1), middle cerebral artery occlusion (neuroprotective, A2), or overlapping genes (PAN)25 or
enrichment of genes induced by neuron interaction (NeurI) or neuron activity (NeurA)31. Point size is scaled by −log10(p value) (Bonferroni adjusted).
b Correlation of top 15 genes of sn-astro-M1–sn-astro-M4. Node size; correlation of the given gene with the module eigengene (kME). c Number of DEGs for
non-neuronal subclusters identified in the Day 5 scRNA-seq dataset with repeated downsampling (10 cells/group/cell type/iteration, 100 iterations; n= 6
mice/group), median (IQR). Summary statistics provided as a Source data file. Macro macrophages, Peri pericytes, ABC arachnoid barrier cells, SMC
smooth muscle cells, VLMC vascular leptomeningeal cells. d Volcano plot of pseudobulk DEGs in astrocytes Day 5, scRNA-seq dataset between FGF1 and
vehicle. Blue, genes with FDR < 0.05; red, genes with FDR < 0.05 and |log2 fold change| > 0.25; green, genes with |log2 fold change| > 0.25; gray, genes
below both thresholds. e Astrocytes WGCNA (Day 5; scRNA-seq) identified three significant upregulated (sc-astro-M1–sc-astro-M3; linear mixed-effects
model; FDR < 0.05) and three downregulated (sc-astro-M5, sc-astro-M6, sc-astro-M9) modules in FGF1-treated mice, median (IQR). Lower panel:
hypergeometric enrichment analysis of single-nucleus RNA-sequencing (snRNA-seq) and scRNA-seq astrocyte modules. Point size is scaled by −log10(p
value) (Bonferroni adjusted; n= 6 mice/group). f Correlation of top 15 genes in modules sc-astro-M1 and sc-astro-M3. g Representative images of
immunoreactivity of aquaporin 4 (Aqp4; red) and glial fibrillary acid protein (GFAP; green) from coronal sections of hypothalamus from diabetic Lepob/ob
mice 1 week after either vehicle or FGF1 icv injection. Lower panels: higher magnification of white inset. Scale bar 100 μm (top), 50 μm (lower). Pixel
dimensions: 0.27 × 0.27 × 2.00microns. Quantification: dots represent volume of Aqp4- or GFAP-positive voxels for individual animals (mean from
2 sections per animal, n= 4/group), mean ± SEM. Unpaired t test, two tailed, *p= 0.037, **p= 0.003 (not adjusted). Source data are provided as a Source
data file. Genes mentioned in the text are labeled in red.
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annotated based on highly enriched genes and revealed a small
cluster of Pomc-expressing cells (Supplementary Fig. 5a). Sur-
prisingly, no neurons in our dataset were assigned with high
confidence to previously characterized Pomc populations.
Agouti-related peptide (Agrp) neurons are the most responsive
neuronal subtype. To estimate which neuronal populations were
most affected 1 day after icv FGF1 injection, we quantified the
amount of DEGs for each neuronal subtype using a repeated
downsampling approach19. This analysis revealed Agrp neurons
to be the most FGF1-responsive neuronal population, with no
other subsets (including Pomc neurons) having a median number
of DEGs > 1 by Day 1 (Fig. 5b; Supplementary Fig. 5b). Utilizing
the pseudobulk approach including all Agrp neurons from Day 1
(n= 313), we identified 47 DEGs (|log2 FC| > 1; FDR < 0.05), of
which 37 were upregulated (Fig. 5c; Supplementary Data 9). To
identify putative biological pathways activated by FGF1 in Agrp
neurons, we subjected upregulated and downregulated DEGs
identified in Agrp neurons to geneset enrichment analysis
(GSEA) and found that, in Agrp neurons, FGF1 increases the
expression of genes involved in both synapse assembly and reg-
ulation of membrane potential (Fig. 5d).
To investigate whether the response in Agrp neurons evolved
over time, we compared Agrp neuron expression profiles between
Day 1 and Day 5 after icv injection. To identify genes that drive
variance in Agrp neurons across these two time points, we
performed PC analysis (PCA) to identify those components
which best separate the four groups (vehicle vs. FGF1, Day 1 vs.
Day 5). In these neurons, the strongest differences in loading
values were in PC4 and PC5, which, respectively, explained 1.9%
and 1.7% of the variation in Agrp neurons and separated FGF1-
Day 1 and FGF1-Day 5 Agrp neurons from the other Agrp
neurons (Fig. 5e). The top loading genes on PC4 overlapped with
genes identified as being significantly upregulated on Day 1,
including Pcdh15 and Kcnq3, suggesting that the effect of FGF1 to
acutely induce expression of these genes in Agrp neurons had
waned by Day 5 (Supplementary Data 10). Pathway enrichment
analysis for negatively loading genes on PC5 (genes with
increased expression in Agrp neurons in the FGF1 Day 5 group)
was suggestive of changes in postsynaptic regulation and function
(Fig. 5f). Furthermore, Agrp and Npy were the two most strongly
positively loading genes on PC5, and expression levels of both
genes were strongly reduced on Day 5 compared to all other
groups (Fig. 5g). By comparison, neither Agrp nor Npy expression
were reduced on Day 1 relative to PF, vehicle-treated controls,
suggesting that the initial response of Agrp neurons to icv FGF1
injection (Day 1) involves alteration of genes implicated in the
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Fig. 4 Icv FGF1 induces a population of differentiating oligodendrocytes. a UMAP clustering of cells in the oligodendrocyte lineage from the Day 5
scRNA-seq dataset. Cell type annotations were inferred from a published dataset35. b Dots represent mean number of cells per animal and lines represent
mean ± SEM. Unpaired t test, two tailed, *p < 0.022, **p < 0.0074 (Bonferroni adjusted; n= 6 mice/group); ns not significant. Source data for each
subcluster are provided as a Source data file. c UMAP of cells in the oligodendrocyte lineage labeled according to maturation in Monocle-derived
pseudotime. d UMAP of cells expressing Gpr17, a maturing oligodendrocyte marker. e RNAScope detection of Gpr17 expression in the hypothalamus of
Lepob/ob mice 5 days after icv FGF1 or vehicle. f Quantification of Gpr17+ cells from the ARC area (2 sections per animal, icv vehicle (n= 4) and icv FGF1
(n= 5)), mean ± SEM. Unpaired t test, two tailed, *p= 0.005 (not adjusted). Source data are provided as a Source data file. NFOL newly formed
oligodendrocyte, MFOL myelin-forming oligodendrocyte, MOL1 myelinating oligodendrocyte.
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5) is predominated by decreased Agrp and Npy gene expression.
Whether these findings are indicative of sustained, FGF1-induced
Agrp neuron inhibition warrants additional study.
FGF1 increases astrocytic contact with neurons. In light of both
the important role played by astrocytes to modulate synaptic
function13–15 and our evidence of a robust transcriptomic and
histochemical response of astrocytes to FGF1, we next sought to
test whether synaptic ensheathment by astrocyte processes is
affected by FGF1. Electron microscopic analysis of the ARC area
on samples obtained following icv injection of either vehicle or
FGF1 in a separate cohort of Lepob/ob mice (n= 4/group) revealed
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Fig. 5 Effects of icv FGF1 on Agrp neurons. a UMAP clustering of neurons from the snRNA-seq dataset that confidently mapped to published datasets16–18.
Original cell type annotations from the published datasets are indicated in brackets. b Numbers of DEGs for neuron subclusters identified using repeated
downsampling (10 cells/group/cell type/iteration, 100 iterations; n= 3 mice/group), median (IQR). c Volcano plot of pseudobulk DEGs in Agrp neurons
from the Day 1 snRNA-seq dataset between FGF1 and vehicle. Red, genes with FDR < 0.05 and |log2 fold change| > 0.25; green, genes with an |log2 fold
change| > 0.25; gray, genes below both thresholds. d Gene Ontology (biological process; red) and REACTOME (blue) terms enriched for DEGs in Agrp
neurons at Day 1. Circle size denotes gene overlap with the identified geneset. e Principal component analysis of Agrp neurons sampled at Days 1 and 5
(vehicle and FGF1) revealed strong separation from other groups at PC4 and PC5, respectively (n= 3 mice/group Day 1, n= 2 mice/group Day 5), median
(IQR). f Gene Ontology term (biological processes) of highly loading genes on PC5. g Normalized expression of Agrp and Npy in Agrp neurons across the 4
groups (FGF1, Days 1 and 5; vehicle, Days 1 and 5; n= 3 mice/group Day 1, n= 2 mice/group Day 5). h Top panel: representative electron microscopic
images of coverage of synapses between axonal boutons (B) and dendritic spines (S) by peri-synaptic astrocytic in the ARC area of Lepob/ob mice. Bottom
panel: immunostaining for Npy. Scale bar 500 nm. Quantification: dots represent percentage of astrocytic coverage for individual animals (mean of
30 synapses per animal, n= 4/group), mean ± SEM. Unpaired t test, two tailed, ***p < 0.0001 (not adjusted). i Contacts between GFAP(+) astrocytes
(green) and Agrp(+) neurons in the ARC area (equivalent to outline in g) 1 week following icv FGF1 or vehicle injection of Lepob/ob. Yellow represents co-
labeled GFAP-positive and Agrp-positive voxels. Scale bar 8 μm. Pixel dimensions: 0.057 × 0.057 × 0.500microns. Quantification: dots represent mean
contact volume over high power field (hpf: 116.5 × 116.5 microns) for individual animals (2 sections per animal, n= 4/group), mean ± SEM. Unpaired t test,
two tailed, **p= 0.0093 (not adjusted). Source data and summary statistics are provided as a Source data file.
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peri-synaptic astrocytic processes that included, but was not
limited to, neurons positive for Neuropeptide Y (NPY; which is
co-expressed with Agrp in ARC neurons; Fig. 5h).
Because these findings were associated with reduced Agrp and
Npy expression levels, and because astrocytes are reported to
modulate the tone of neurons in the melanocortin system15, we
next asked whether physical interactions between astrocytes and
Agrp neurons are induced by icv FGF1 injection. Consistent with
this hypothesis, co-staining for GFAP and Argp performed
1 week following icv FGF1 (or vehicle) injection in a separate
cohort of Lepob/ob mice reveals a marked increase of cellular
contacts between GFAP(+) astrocytes and Agrp neurons induced
by FGF1 in the ARC area (Fig. 5i). These findings point to a
model in which the astrocyte response to FGF1 involves changes
in synaptic function within hypothalamic neurocircuits relevant
to glucose homeostasis. Such an effect need not be limited to
Argp neurons, and further studies are warranted to determine
whether and how enhanced glia–neuron interactions in the
hypothalamus might contribute to the sustained antidiabetic
action of FGF1.
Dependence of FGF1-induced diabetes remission on melano-
cortin receptor signaling. Reduced melanocortin signaling is
linked to diabetes pathogenesis in both rodents and humans38–41.
Because Agrp neurons are the most responsive neurons after
FGF1 injection, and since these neurons function as endogenous
inhibitors of melanocortin signaling, we next asked whether
sustained antidiabetic action of FGF1 depends on intact mela-
nocortin signaling. To this end, we tested whether either mice
lacking the melanocortin 4 receptor (Mc4r; Mc4r−/−) or agouti
(KK-Ay) mice (in which obesity and T2D (depending on the
background strain) result from ectopic overexpression of Agouti,
an Agrp homolog42) are resistant to the sustained antidiabetic
response to icv FGF1 injection. We found that, whereas both
Mc4r knockout and KK-Ay mice exhibited the rapid reduction of
food intake and BG levels typical of Lepob/ob mice following icv
injection of FGF1 (3 µg)4 (Figs. 1a and 6a, b), BG levels returned
to baseline within 10–14 days in both mouse strains, unlike the
prolonged normoglycemia induced by icv FGF1 injection in
Lepob/ob mice4. Whereas intact melanocortin signaling is not
required for initial anorexia and glucose lowering, these findings
suggest that it is required for the sustained antidiabetic action
induced by icv FGF1 injection.
To test this hypothesis further, we generated four groups of
Lepob/ob mice, each of which received two separate icv treatments:
a single icv injection of either FGF1 (3 µg) or vehicle, followed
immediately by continuous icv infusion of either vehicle or the
Mc4r antagonist, SHU9119 (5 nmol/day) for 28 days. Whereas
food intake, body weight (BW), and BG levels did not change in
icv vehicle-injected mice, regardless of whether they also received
continuous icv infusion of vehicle or SHU9119 (Fig. 6c;
Supplementary Fig. 6), icv FGF1 injection elicited both the
expected initial reduction of food intake and the long-lived
normalization of glycemia when it was coupled to continuous icv
infusion of vehicle. When icv FGF1 injection was combined with
continuous SHU9119 infusion, however, remission of hypergly-
cemia was not sustained even though the transient effects of icv
FGF1 to reduce food intake, BW, and BG levels remained intact
(Fig. 6c; Supplementary Fig. 6). Statistical analysis (Supplemen-
tary Notes) confirmed that, whereas icv SHU9119 infusion had
no effect on transient reductions of food intake and glycemia
induced by FGF1, it fully blocked sustained diabetes remission
(Chi square (3)= 10.3, p= 0.016 (not adjusted)). These findings
collectively demonstrate that, although increased melanocortin
signaling is not required for the acute, transient effects of icv
FGF1 injection on energy balance and glycemia, it is required for
sustained diabetes remission.
Long-term hypothalamic changes induced by icv FGF1. To
investigate the durability of transcriptional responses elicited by
icv FGF1, we generated bRNA-seq datasets from hypothalami of
independent cohorts of Lepob/ob mice on Days 1, 5, and 42 post-
icv FGF1 injection and compared the results to PF, vehicle-
treated controls. DEG analysis revealed profound transcriptional
changes at Day 1 that dissipated by Day 42 (|log2 FC| > 0.5; FDR
< 0.05) Fig. 7a–c; Supplementary Data 11). Using rank–rank
hypergeometric overlap analysis (RRHO)43 to identify
transcriptome-wide patterns across the three time points, we
identified a robust overlap in genes that were upregulated both at
Days 1 and 5 as well as genes that were upregulated at Day 1 and
downregulated at Day 5. As expected, among the upregulated
genes at both time points were Gfap, Vim, and S100a10 (another
glial marker gene) consistent with the snRNA-seq analyses of a
shared reactive glia response, while Aqp4 and Gpr17 and Bmp4 (a
COP marker gene) were upregulated only at Day 5 likewise
confirming the single-cell analyses (Fig. 7c). Pathway enrichment
analysis of co-upregulated genes indicated extracellular matrix
remodeling and integrin signaling. Likewise, genes upregulated at
Day 1 and not coherently regulated at Day 5 enriched for ribo-
some biogenesis, mirroring the dissipating response seen in
tanycytes and ependymal cells. The Day 5 vs. Day 42 comparison
revealed a strong overlap between genes upregulated at Day 5 and
downregulated at Day 42. These genes enriched for pathways
indicative of glial activity (e.g., “cilium assembly” and “gliogen-
esis”), suggesting that most of the robust glial responses observed
on Days 1 and 5 had waned by Day 42 (Fig. 7b).
However, Agrp expression remained significantly downregu-
lated in FGF1-treated mice compared to controls on Day 42 (log2
FC=−1.33 ± 0.39; p= 6.0 × 10−4; Bonferroni significance
threshold, p < 0.05/30). This analysis also detected Pomc expres-
sion at low levels at each of the 3 time points, with a significant
increase detected 1 day after FGF1 treatment (log2 FC=−1.66 ±
0.46; p= 2.9*10−4; Bonferroni significance threshold, p < 0.05/
30). While this finding raises the possibility of Pomc neuron
activation as an early component of the neuronal response to
FGF1, by Day 42 Pomc levels had returned to those of vehicle-
treated controls. To validate these observations, we performed a
targeted analysis using reverse transcription polymerase chain
reaction (RT-PCR), which confirmed that, 42 days after a single
icv injection of FGF1 in Lepob/ob mice, Agrp expression was
indeed reduced compared to vehicle controls, albeit not
significantly when adjusting for multiple testing (p= 0.042;
Bonferroni significance threshold, p < 0.05/3). Expression of Npy
mRNA showed a similar trend at this late time point, but the
effect did not achieve statistical significance, while Pomc
expression was unchanged (Fig. 7d, e).
Among the most upregulated genes on Day 42 in Lepob/ob mice
receiving FGF1 was Mef2c (Fig. 7d), which encodes a transcrip-
tion factor that influences synaptic plasticity44. Furthermore,
threshold-free GSEA on the Day 42 data indicated increased
activity in neuronal pathways including “long-term synaptic
potentiation”, “glutamate receptor signaling” and “regulation of
synaptic plasticity”, while genes involved in “regulation of
transmission of nerve impulse” were decreased (Fig. 7f; Supple-
mentary Data 12). Because long-term presynaptic silencing can
cause synaptic accumulation of dense-core vesicles (DCVs;
neuronal organelles that contain neuropeptides)45,46, we investi-
gated whether synaptic content of DCVs is affected by icv FGF1
injection. Thus electron microscopy was employed to evaluate
110 synapses from the MBH of Lepob/ob mice (n= 4/group) that
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received icv injection of either FGF1 or vehicle and were
sacrificed 28 days later. The average number of DCVs/synapse/
mouse was increased in mice receiving FGF1 by 67% (p= 0.010;
Fig. 7g). Taken together, these findings offer indirect support for a
model in which FGF1 induces sustained changes in presynaptic
plasticity (afferent and/or local inputs) in the ARC area that
contribute to long-term changes in circuit computations involved
in central control of glucose homeostasis. Based on this model, we
speculate thatMef2c induction by FGF1 contributes to a sustained
reduction in the excitability of hypothalamic neurocircuits that
raise the BG level when activated, leading to synaptic DCV
accumulation and potentially contributing to sustained ameliora-
tion of hyperglycemia. Future studies are warranted to investigate
this model.
Discussion
Until recently, the brain’s ability to ameliorate hyperglycemia in a
sustained manner in diabetic animals was unrecognized. Based on
the untapped therapeutic potential of such an effect, the current
work was undertaken to identify and characterize the response of
diverse hypothalamic cell types to FGF1, with the ultimate goal of
linking these responses to the sustained antidiabetic action of this
peptide. To this end, we combined an unbiased, discovery-based
transcriptomics approach with histochemistry, electron micro-
scopy, and in vivo pharmacological and physiological studies. We
identified dramatic transcriptional and morphological changes in
both tanycytes and astrocytes in the days following icv FGF1
injection. At the ultrastructural level, increased astrocyte coverage
of synaptic boutons was detected on dendritic spines of ARC
neurons, including Agrp neurons. The transcriptome of Agrp
neurons was also strongly altered following icv FGF1 adminis-
tration, including a sustained inhibition of both Agrp and Npy
expression. These observations raise the possibility that Agrp
neuron function is altered as a consequence of FGF1 action on
glial cells, and additional work is warranted to asses this possi-
bility. If so, we would infer that the sustained glucose-lowering
effects of central FGF1 involve actions on one or more hypo-
thalamic glial cell types that in turn alter glucoregulatory neu-
rocircuit function in a highly durable manner. To our knowledge,
such an effect has not previously been reported.
Of particular interest was the response of tanycytes, which line
the 3V and project long filamentous processes into adjacent
hypothalamic nuclei involved in glucose homeostasis. These cells
have glucose-sensing properties and are implicated as participants
in hypothalamic control of metabolism9,10,28,47. Among the
canonical signal transduction pathways activated downstream of
FGF receptor activation is the MAPK-ERK pathway, and we
recently reported that icv FGF1 injection rapidly induces MAPK-
ERK signaling in tanycytes and ependymal cells lining the 3V5. It
is therefore unsurprising that, within 24 h of icv FGF1 injection,
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Fig. 6 FGF1-induced sustained diabetes remission is melanocortin dependent. a Blood glucose levels and food intake in diabetic Mc4r−/− (Mc4r
knockout) mice injected with icv FGF1 (3 µg) or vehicle (n= 8/group). b Blood glucose levels and food intake in agouti (KK-Ay) mice icv injected with FGF1
(3 µg) (n= 12) or vehicle (n= 9). Vehicle-injected mice were not pair-fed to the intake of mice receiving FGF1. c Blood glucose levels and food intake of
diabetic Lepob/ob mice treated with either a single icv injection of FGF1 (3 µg) or vehicle, followed immediately by continuous icv infusion of either vehicle or
the Mc4r antagonist SHU9119 (5 nmol/day) for 28 days. Veh+Veh (n= 8), FGF1+Veh (n= 9), Veh+SHU (n= 6), FGF1+SHU (n= 8). Data are
represented as mean ± SEM, source data are provided as a Source data file.
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Fig. 7 FGF1-induced long-term changes in the hypothalamus. a Number of DEGs (|log2 fold change| > 0.5; FDR < 0.05) from bulk RNA-sequencing
(bRNA-seq) of hypothalami from Lepob/ob mice injected with icv FGF1 or vehicle and harvested Days 1 (FGF1 n= 10, vehicle n= 4), 5 (FGF1 n= 9, vehicle
n= 7), and 42 (n= 5 mice/group) after injection. Control vehicle mice were pair-fed to FGF1-injected mice. b Rank–rank hypergeometric overlap maps of
the degree of overlapping genes between Day 1 and Day 5 (top) and between Day 5 and Day 42 (bottom). Venn diagrams and top overlapping genes
(middle panel). Enrichment of Gene Ontology biological process terms of overlapping genes (right panel). c Normalized counts (mean ± SEM, n= 5 mice/
group) of the selected glial genes from the bRNA-seq datasets Days 1, 5, and 42 after icv FGF1 or vehicle injection. d Normalized counts (mean ± SEM, n=
5 mice/group) of Agrp, Npy, Mef2c, and Pomc expression Days 1, 5, and 42 after icv FGF1 or vehicle injection. e Targeted relative gene expression of Agrp,
Npy, and Pomc. Unpaired t test, two tailed, *p= 0.04 (not adjusted, n= 5 mice/group); ns not significant. Source data are provided as a Source data file.
f Threshold-free geneset enrichment analysis (Gene Ontology biological processes terms) of DEGs identified in bRNA-seq data at Days 1, 5, and 42. Point
size is scaled by −log10(p value) (Bonferroni adjusted) and is colored based on the normalized enrichment score (NES). g Representative electron
microscopic images of synapses of Lepob/ob mice 5 days after icv injection of either vehicle or FGF1. syn synaptic active zone, DCV dense-core vesicle, SV
small light-core vesicle. Scale bar 500 nm. Quantification: dots represent mean %DCV/synapse per mouse (25 synapses per animal, n= 4/group).
Unpaired t test, two tailed, *p= 0.01 (not adjusted); ns not significant. Source data are provided as a Source data file. Data are presented as mean ± SEM.
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genes known to be involved in the ERK cascade (including Spry2
and Spred112). Moreover, since tanycytes are implicated in ATP-
dependent brain glucose sensing47, it is of interest that genes
involved in glycolysis (which generates cytosolic ATP) were also
upregulated in tanycytes at Day 5. Additional study is warranted
to ascertain the contribution of these robust tanycyte responses to
FGF1-induced normalization of glucose homeostasis.
In astrocytes, the most consistently upregulated genes are
involved in neuroprotection. These include Aqp4, Sparcl1, and the
glutamate transporters Slc1a2 and Slc1a3, as well as Clu, Cpe, and
Ntrk2. The latter is of interest because it encodes TrkB, the
receptor for brain-derived neurotrophic factor (BDNF). Like
FGF1, BDNF administration can ameliorate hyperglycemia in
mouse models of T2D whether administered peripherally48 or
when given icv at lower doses49, and BDNF is also implicated as
an axon guidance cue for ARC neurons innervating adjacent
hypothalamic areas during postnatal development50. Upregula-
tion of TrkB in astrocytes is therefore of interest as a potential
way to influence glucoregulatory neurocircuit organization.
Astrocytes also provide essential homeostatic support to neu-
rons via multiple mechanisms. Among these are peri-synaptic
astrocyte processes (PAPs) which, together with the presynaptic
and postsynaptic terminals, comprise the “tri-partite synapse”13.
As PAPs are essential both to normal synaptic function and to
neuroprotection following brain injury25, our finding that PAP
coverage of dendritic spines on ARC neurons was increased
5 days after icv FGF1 injection identifies a potential mechanism
whereby FGF1 influences synaptic function of hypothalamic
neurons involved in glucose homeostasis. This possibility is fur-
ther strengthened by our finding that genes involved in
astrocyte–neuron crosstalk31 were also upregulated in astrocytes
and that FGF1 markedly increased cellular contacts between
astrocytes and Agrp neurons.
With the observations that (1) morphological changes of
hypothalamic astrocytes (astrogliosis) induced by high-fat
feeding15,51 are associated with altered activity of both Pomc
and Agrp neurons15 and (2) impaired melanocortin signaling is
implicated in the pathogenesis of T2D in both humans and
rodent models38–41, we hypothesized that the melanocortin sys-
tem is a target for sustained diabetes remission induced by FGF1.
Consistent with this notion, we report that sustained diabetes
remission is not observed when icv FGF1 is given to diabetic mice
with genetic impairment of melanocortin signaling (agouti mice,
Mc4r−/− mice), nor is it observed when melanocortin signaling is
blocked pharmacologically in Lepob/ob mice (by icv infusion of an
Mc4r antagonist). Combined with evidence that this effect of
melanocortin blockade was observed despite the fact that FGF1-
induced anorexia was unaffected, these findings imply that,
whereas the sustained antidiabetic action of FGF1 is melanocortin
dependent, the transient anorexic response is not. Based on these
collective findings, we hypothesize that the antidiabetic action of
FGF1 involves robust effects on hypothalamic glial cell types that
in turn trigger sustained changes in the melanocortin system and
perhaps other, as yet unidentified, glucoregulatory neurocircuits.
One limitation of the current work is that we identified only a
small subset of Pomc neurons, possibly owing to the marked
reduction of Pomc gene expression characteristic of Lepob/ob
mice52,53. Nevertheless, we did observe an increase of Pomc
expression in the bRNA-seq data on Day 1. If this response was
accompanied by increased α-melanocyte-stimulating hormone
release and binding to Mc4r, the resultant increase of melano-
cortin signaling might have played a role in the response to FGF1,
potentially augmented by concomitant Agrp neuron inhibition.
Additional investigation into the roles played by Pomc and Agrp
neurons in the sustained antidiabetic action of FGF1 will be of
considerable interest.
Another limitation inherent in transcriptomics research is that
induced genes may or may not be translated into protein. We
addressed this issue by employing IHC, in situ hybridization, and
electron microscopy, but additional work is needed to clarify the
physiological relevance of many of the observed transcriptional
responses. Outstanding questions include: Which transcriptomic
responses and cell types are direct targets for the effect of FGF1
on the melanocortin system? Which are affected secondarily?
How do these changes evolve over time? What other glucor-
egulatory neurocircuits might be similarly affected?; And, which
of these cellular responses are relevant to how the brain senses the
circulating glucose level? Studies to address these questions are an
important priority.
That a single icv injection of FGF1 is sufficient to re-set the
defended level of glycemia to normal in rodent models of
T2D4,5,11 is a finding of substantial therapeutic relevance.
Ongoing efforts to bridge the gap between diverse cellular
responses to FGF1 and the associated normalization of glycemia
may ultimately uncover novel strategies for achieving sustained
diabetes remission.
Methods
Mice. All procedures were either performed in accordance with the NIH Guide for
the Care and Use of Laboratory Animals and were approved by the Institutional
Animal Care and Use Committee at the University of Washington, Novo Nordisk
Research Center Seattle, and St. Joseph’s Hospital and Medical Center or per-
formed with approved protocols from The Danish Animal Experiments Inspec-
torate permit number 2014–15–0201–00181 and the University of Copenhagen
project number P16-122. Male, 6–8-week-old Lepob/ob (B6.Cg-Lepob/J), 6-week-old
KK-Ay (KK.Cg-Ay/J), and Mc4r−/− (B6; 129S4-Mc4rtm1lowl/J) mice were purchased
from Jackson Laboratories (Bar Harbor, ME, USA) and 8-week-old Lepob/ob (B6.V-
Lepob/JRj) mice were purchased from Janvier Labs, France.
Surgerized animals were individually housed under specific pathogen-free
conditions in a temperature-controlled room, with 75–80% humidity and with a
12:12 h light:dark cycle and provided with ad libitum access to water and Purina
5008 chow (Animal Specialties, Inc., CA, USA) or Altromin 1310 chow
(Brogaarden, Denmark) unless otherwise stated. Mice were allowed to acclimatize
at least 7 days before surgery. After surgery, Mc4r−/− mice were allowed to
acclimatize for 2 weeks and subsequently put on a high-fat, high-sucrose diet
(F1850, Cholesterol (0.15%), Paste; Bio-Serv, NJ, USA) to induce hyperglycemia.
Surgeries and icv injections. Cannulation of the lateral ventricle (LV; 26-ga,
Plastics One, Roanoke, VA) were performed under isoflurane anesthesia in either
Lepob/ob or KK-Ay mice, using the following stereotaxic coordinates: −0.7 mm
posterior to bregma; 1.3 mm lateral, and 1.3 mm below the skull surface4. Animals
received buprenorphine hydrochloride (Reckitt Benckiser Pharmaceuticals Inc.,
Richmond, VA) or Rimadyl (5 mg/kg, Pfizer, NY, USA) postoperatively and were
allowed to recover for at least 7 days before study, while food intake and BW were
recorded. Mice whose BW had not recovered 7 days after surgery were excluded
from the study.
Mice were closely monitored to ensure matched BW and BG levels between
study groups. Lepob/ob, Mc4r−/−, and KK-Ay mice that did not exceed BG of 250
mg/dl for 3 consecutive days were not considered diabetic and were excluded from
the study. Recombinant human FGF1 (hFGF1 from Novo Nordisk A/S, Denmark)
was dissolved in phosphate-buffered saline (PBS) at a concentration of 1.5 μg/μl.
Mice were injected with either hFGF1 or vehicle (PBS) over 60 s in a final volume
of 2 μl using a 33-gauge needle extending 0.8 mm beyond the tip of the icv cannula.
Food intake, BW, and BG were recorded daily for mice receiving hFGF1 for 5 days
and vehicle control mice were pair-fed to the mean amount eaten by hFGF1-
injected mice for 5 days.
To determine whether the effect of icv FGF1 to induce sustained remission of
hyperglycemia in Lepob/ob mice is dependent on melanocortin signaling, we
commenced infusion of either saline vehicle or the melanocortin receptor
antagonist SHU9119 (SHU, Bachem Americas, Inc., CA) immediately after
administering a single icv injection of either saline vehicle or recombinant mouse
FGF1 (3 µg; Prospec, NJ, USA) in a volume of 2.5 µl to male Lepob/ob mice in a
volume of 2.5 μl as follows. Thus four groups of animals were studied: Group 1:
vehicle (saline)+ vehicle, Group 2: vehicle+ FGF1 (3 µg), Group 3: SHU (5 nmol)
+ FGF1, and Group 4: SHU+ vehicle. Vehicle or SHU (5 nmol/day) was
continuously administered to Groups 1–2 or Groups 3–4, respectively, for 4 weeks
using an osmotic minipump (ALZET, DURECT Corporation, CA) that was
connected to an icv injector (PlasticOne) with polyethylene tubing (Tygon) and
subsequently implanted subcutaneously to enable direct infusion of either vehicle
or SHU. The injector was inserted into the LV cannula and fixed with both instant
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and orthodontic adhesives immediately following a single icv injection of either
vehicle or FGF1.
Generation of single-nucleus suspensions. Hypothalamic punches (2 mm) (Day
1, n= 3/group; Day 5, n= 2/group) were rapidly extracted between 9 and 12 a.m.,
dissected, and then placed ventral surface up into a chilled stainless steel brain
matrix. A single coronal section (1.5-mm thick) block was obtained between the
rostral and the caudal ends of the Circle of Willis, followed by a hypothalamic
punch (2 mm), which was immediately frozen on dry ice and stored at −80 °C until
further processing. For the single-nuclei dissociation, frozen hypothalamic punches
were recovered in 1 ml ice-cold EZ PREP buffer (Sigma) and homogenized using 2
ml glass dounce tissue grinders; 10 times with pastel A and 10 times with pastel B,
followed by 5-min incubation on ice. Homogenate was transferred to clean tubes
and centrifuged at 500 × g for 5 min at 4 °C. Supernatant was removed followed by
an additional 5 min incubation on ice in 1 ml EZ PREP buffer and centrifuged at
500 × g for 5 min at 4 °C. The pellet was washed first in 1 ml PBS (Gibco) with 1.0%
bovine serum albumin (BSA) and centrifuged at 500 × g for 5 min at 4 °C followed
by a 500 ml PBS+ 0.1% wash containing LIVE/DEAD stain (Life Technologies) to
ease nuclei visualization. Debris and myelin were removed from the resuspended
nuclei by a 1.80 M sucrose gradient centrifugation step according to the manu-
facturer’s protocol (Nuclei PURE Prep Isolation Kit, Sigma). Nuclei were subse-
quently washed in 1 ml PBS+ 1.0% BSA, filtered through a 40-mm mesh (Falcon),
centrifuged at 500 × g for 5 min at 4 °C, and resuspended in 50–150 ml PBS+ 1.0%
BSA. Nuclei concentration was estimated by counting on a hemocytometer (iChip)
and kept on ice until single-cell encapsulation.
Generation of single-cell suspensions. Mice (n= 6/per group) were euthanized
and brains were rapidly extracted, cooled in ice-cold Dulbecco’s modified Eagle’s
medium/F12 media (Gibco, Thermo Fisher Scientific) for 5 min. Dissection of the
brain was performed as above followed by a triangular section of the MBH using a
scalpel. Dissected tissue was digested using a Neural Tissue Dissociation Kit
(Miltenyi Biotec, Bergisch Gladbach, Germany) with manual dissociation with the
following modifications: sections were immediately placed in preheated (37 °C)
enzyme mix 1 (1425 ml Buffer X+ 37.5 ml Enzyme E) and incubated in closed
tubes for 15 min at 37 °C under slow, continuous rotation. Then enzyme mix 2 (15
ml Buffer Y+ 7.5 ml Enzyme A) was added followed by mechanically dissociated
using a wide-tipped, fire-polished Pasteur pipette by pipetting up and down 10
times slowly. After a 10-min incubation under slow, continuous rotation, using a
series of 2 fire-polished Pasteur pipettes with incrementally smaller openings the
tissue was gently dissociated until no visible pieces were observed. Cell suspensions
were centrifuged at 300 × g for 10 min at room temperature (RT) and resuspended
in 500 ml Hanks’ Balanced Salt Solution (HBSS) (catalog # 14025092, Gibco,
Thermo Fisher Scientific) and 0.04% (w/v) BSA (catalog # A9418, Sigma-Aldrich).
Following an additional wash (centrifugation at 300 × g for 5 min and re-
suspension in 100 µl HBSS+ 0.04% BSA), cells were filtered through a 40-mm
mesh, and 50 ml HBSS+ 0.04% BSA was added through the filter and transferred
to clean tubes. The cell suspension was centrifuged at 300 × g for 5 min and
resuspended in 50–150 ml HBSS+ 0.04% BSA. Cell concentrations were estimated
on a NucleoCounter NC-3000 (Chemometec, Denmark) and kept on ice until
single-cell encapsulation.
Generation of bulk RNA-seq data. Following euthanasia, brains (Day 1, n= 4
vehicle; n= 10 FGF1; Day 5, n= 7 vehicle; n= 9 FGF1; Day 42, n= 42/group)
were dissected as for snRNA-seq and immediately frozen on dry ice and stored at
−80 °C until further processing. RNA was isolated using the Qiagen RNeasy Mini
Kit (catalog # 74104), followed by high capacity cDNA reverse transcription (from
Applied Biosystems, catalog # 4368813), and finally analysis was carried the using
Agilent RNA 6000 Nano Kit. The RNA sample concentration was between 200 and
350 ng/μl, with 10–15 μg purified RNA from each individual sample. All RNA
samples showed a good purity (A260/280 ratios are between 2.0 and 2.1), and
Bioanalyzer results demonstrated a good quality of RNA for all samples (RIN
numbers > 9.2). Sample mRNA libraries were prepared using the Illumina mRNA
True Strand Kit (Covance Genomics Lab, Redmond, WA; Seattle Genomics Core,
Seattle, WA) and sequenced on either an Illumina HiSeq 2500 system to generate
100 bp paired end libraries with 20–30 million reads (Covance Genomics Lab,
Redmond, WA) or Illumina NovaSeq 6000 system on an S1 flow cell yielding
approximately 35 million (2 × 50 bp) paired end reads.
Single-cell RNA sequencing. Single-cell cDNA libraries were generated using the
Chromium single-cell platform and the 3′ v2 Reagent Kit according to the man-
ufacturer’s protocol (10× Genomics, USA). Single-cell libraries were sequenced on
a NextSeq 500 platform (3 samples (whole single cells) and 2 samples (single
nuclei) on one flow cell) to obtain 100- and 32-bp paired end reads using the
following read length: read 1, 26 cycles, read 2, 98 cycles and i7 index, 8 cycles.
Single-cell RNA-seq and single-nucleus RNA-seq data processing. Cell Ranger
version 1.2 (10× Genomics, USA) was used to de-multiplex and quantify UMIs. A
count matrix was generated for each sample with default parameters and genes
were mapped to the mouse reference genome GRCm38 (mm10, part of the Cell
Ranger software package; for the scRNA-seq dataset) or an adapted reference from
mouse reference genome including introns (for the snRNA-seq dataset), following
the steps outlined on the 10× Genomics website (https://support.10xgenomics.
com/single-cell-gene-expression/software/pipelines/latest/advanced/
references#premrna). Barcodes were filtered to include those with a total UMI
count >10% of the 99th percentile of the expected recovered cells.
Quality control of single-cell and single-nucleus expression data. Scrublet54
was run with default parameters to identify likely doublets (this step was omitted
for the snRNA-seq data), which were subsequently removed from the expression
matrix. Further processing was performed using the Seurat55 R package (version
2.3). Cells in which <400 or >4000 expressed genes were detected, as well as any cell
with >20% (>5% for snRNA-seq) mitochondrial and/or ribosomal transcripts, were
discarded. Genes detected in <10 cells (<5 cells in the snRNA-seq data) were also
removed. Counts were normalized using the SCtransform() from Seurat. Variable
genes were identified using the FindVariableGenes() function with default settings.
Unwanted sources of variation, e.g., number of UMI and ribosomal and mito-
chondrial percentage, were regressed out using the ScaleData() function. PCs were
found with variable genes using the RunPCA() function. The top 30 PCs were used
to identify clusters and with the FindClusters() function at a resolution of 0.1.
Single-nucleus RNA-seq data clustering. UMAP projection of snRNA-seq data
revealed a strong batch effect between samples in this dataset. To identify con-
served populations between all samples, sample datasets were integrated using the
Seurat commands FindIntegrationAnchors() and IntegrateData(). Following inte-
gration, the data were processed as described above. Following identification of
marker genes with the FindMarkers() function, literature was searched for cell-
specific genes to determine cluster identity. At this low-resolution clustering, we
removed ambiguously mapping cells by identifying cells with low silhouette scores
<0 and removed them from the dataset (https://perslab.github.io/bentsen-rausch-
2020/). Finally, the data were re-clustered to identify major cell populations.
Single-cell RNA-seq data clustering and identification of cell types. The
scRNA-seq data showed much reduced batch effect as compared to the snRNA-seq
data, so the integration step was unnecessary. Following identification of marker
genes with the FindMarkers() function, literature was searched for cell-specific
genes to determine cluster identity. All neuronal lineage cells were removed from
this dataset, as the quality was poor due to mouse age (myelination/neuron fra-
gility). The final step was to further remove any artifacts/doublets, which had been
missed in the initial round of processing. Each cell type underwent a round of
iterative clustering as described above. Within each cell type, any cluster in which
50% of cells originated from a single sample was removed. The FindMarkers()
function was used to identify markers of each subcluster, which were removed if
enriched for marker genes of a different cell type. Finally, all remaining cells were
merged to create the final dataset, and clustering was performed again with the
same settings as above.
Label projection. To identify canonical hypothalamic neuron populations, we
downloaded three existing single-cell studies characterizing cell types in the MBH
region. The raw data were processed with Seurat using default parameters and
original labels were maintained. The projection was performed iteratively in that
we first took the Campbell et al.16 data (GSE93374) and used the FindTransfer-
Anchors() and TransferData() commands (default settings, 30 dimensions) to
transfer labels to the query data. All cells that were assigned a label with >75%
confidence were removed from the query dataset. We then performed label pro-
jection using the Chen et al.18 (GSE87544) and the Romanov et al.17 (GSE74672)
datasets as described above. All mapped cells were then extracted and reclustered as
described above. Clusters were annotated based on marker genes and the projected
label that appeared most times in the identified cluster.
Differential gene expression resampling. A strong driver of differential
expression in single-cell data is the cell number. To control for this, our resampling
procedure randomly selects ten cells per cluster per sample for pseudobulk analysis
(see below). The test was performed 100 times per cluster to generate a distribution
of DEGs. Bonferroni adjustment was used to account for multiple testing.
Pseudobulk analysis. Pre-determined clusters were split by sample. Raw counts
were summed across each gene per sample to generate a single column per sample.
This matrix was then fed directly into DESeq2 tool (version 1.22.2)56 for standard
processing.
Pathway enrichment analysis for pseudobulk results. DEGs were tested for
functional enrichment of GO (GO:BP category)20, REACTOME21, and KEGG22
pathways using the gProfiler R package57. gProfiler parameters were adjusted to
indicate the use of an ordered query, limit testing to pathways containing between
10 and 300 genes, a minimum intersection size of 3 genes, and a strong hierarchical
filtering of GO terms. A custom background was set for all analyses to include all
genes that were used for DESeq2 analyses. A z-score was calculated for each term
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by calculating the number of upregulated minus downregulated genes divided by
the square root of the number of genes that overlapped within a term.
WGCNA and adjacency matrix calculation. The WGCNA package (version 1.66)23
implemented in R was used. Pearson correlation coefficient was used for the single-cell
data and signed network parameter was used to compute the gene–gene adjacency
matrix. Powers corresponding to the top 95th percentile of network connectivity or
above were discarded and the lowest soft threshold power between 1 and 30 to achieve a
scale-free topology R-squared fit of 0.8 was selected.
WGCNA hierarchical clustering. The topological overlap matrices were converted
to distance matrices, and the hclust() function was used with the average (clusters
<3000 cells) or complete (clusters >3000 cells) method to cluster genes hier-
archically. The cutreeDynamic() function was used with a deepSplit parameter of 2
(clusters >3000 cells) or 4 (clusters <3000 cells) and the pamStage parameter set to
FALSE to carve the dendrogram into modules with at least 15 genes. The merge-
CloseModules() function was used to compute module eigengenes, the vector of cell
embeddings on the first PC of each module’s expression submatrix. The same
function was used to merge modules, using a cutHeight of ≤0.2, corresponding to a
Pearson correlation between module eigengenes of ≥0.8. The module eigengenes
and expression matrices were used with the signedKME() function to compute
gene–module Pearson correlations, or kMEs, a measure of how close each gene is to
each module. Module treatment associations were tested using a linear mixed-
effects model with the nlme R package58 (function lme()), using a random effect for
each sample. Treatment and batch were modeled as fixed effects to control for
variation between samples. Significance values are FDR corrected to account for
multiple testing.
Geneset enrichment analysis. Genes within each module were ordered based on
their module membership (kME) and tested for functional enrichment of GO:BP
terms20, REACTOME21, and KEGG22 pathways using the gProfiler R package57.
gProfiler parameters were adjusted to indicate the use of an ordered query, limit
testing to pathways containing between 10 and 300 genes, a minimum intersection
size of 3 genes, and a strong hierarchical filtering of GO terms. A custom back-
ground was set for all single-cell analyses to include only the 5000 most variable
genes, which were used for WGCNA-based analyses.
Tanycyte analysis. Labels were propagated from the Campbell et al. dataset16
(GSE93374) using the Seurat (version 3.0) SCTintegration() pipeline with default
settings and 30 dimensions. All cells that were assigned a label with >50% con-
fidence were further analyzed. PCA was performed on all tanycytes using the
RunPCA() function in Seurat. Upon identification of a gene expression continuum
in PC1/PC2, the princurve R package59 was used with default settings to fit a
principal curve to the data. Each cell was assigned a lambda value along the
principal curve to be used as a measure of pseudoventricle height. To calculate the
effect of FGF1 on module expression over pseudoventricle height, module
expression was binned with a width of 1. Average expression and SEM was cal-
culated at each pseudoventricle value. Linear regression was performed to identify
significant changes in expression.
Astrocyte analysis. To better characterize genesets induced in astrocytes by FGF1,
hypergeometric enrichment was performed to test whether the genesets enriched
for markers of astrocytes in middle cerebral artery occlusion (MCAO)/lipopoly-
saccharide (LPS) mice or astrocytes co-cultured with neurons. Prior to the analysis,
the Zamanian et al.25 (GSE35338) and Hasel et al.31 (E-MTAB-5514) datasets were
downloaded and DEG analysis was performed. Genesets were constructed by
identifying any gene with a log2 FC > 2 and FDR < 0.05 (omitted for the Zamanian
et al.25 dataset) in any of the conditions described. Any genes shared between LPS
and MCAO at Day 1 were assigned to the PAN-reactive geneset. Furthermore, any
gene found to overlap between LPS and MCAO was removed from the geneset. All
p values were FDR corrected.
Oligodendrocyte analysis. Labels were propagated from Marques et al.35
(GSE75330) using the Seurat pipeline with default settings and 30 dimensions.
All cells which were assigned a label with >50% confidence were further ana-
lyzed. Shifts in cell type abundance across conditions were tested using the
Student’s t test. To further analyze the effects of FGF1 on oligodendrocytes, a
pseudo-developmental timeline of oligodendrocyte differentiation was built
with Monocle236. Cells were ordered based on genes that differ between clus-
ters, a procedure referred to as dpFeature. tSNE dimensional reduction was
performed using two PCs. Cells were then clustered in this with the clusterCells
() command with a local density (p value) value of 150 and a nearest distance of
a cell (delta) value of 15. DEGs between clusters were identified with the dif-
ferentialGeneTest() command. The top 1000 DEGs were extracted for cell
ordering. The pseudotime axis of differentiation was determined based on the
expression of previously established markers.
Bulk RNA-seq data processing and differential gene expression analysis. The
RNA-seq sequences were aligned to the Mus musculus reference genome build
Grch38 (release 77) using the STAR aligner60. The resulting count data were
quantile normalized and used for downstream analysis. The resulting count matrix
were analyzed with DESeq2 to perform count normalization and differential
expression analysis between treatment groups.
RRHO analysis. Gene lists from each time point were ranked by t-statistics. RRHO
was then used to evaluate the transcriptome-wide overlap of these lists using the
web application at https://systems.crump.ucla.edu/rankrank/rankranksimple.
php43.
IHC, microscopy, and image analysis. IHC of diabetic Lepob/ob mice treated with
icv FGF1 (3 μg) or vehicle were perfused 7 days after injection with saline and 4%
paraformaldehyde (PFA), post-fixed overnight at 4 °C, and then sectioned using a
vibratome (50 µm). For immunostaining, sections were incubated in primary and
secondary antibodies in PBS/0.5% Triton-X100 and 5% normal goat serum for
24–48 h at 4 °C. Primary antibodies were chicken anti-vimentin (1:500, EMD
Millipore AB5733), mouse anti-GFAP (1:500, EMD Millipore MAB3402), rabbit
anti-Aquaporin 4 (1:200, EMD Millipore AB3594), and rabbit anti-Agrp (1:1000,
Phoenix Pharmaceuticals, Inc., 003–53). Secondary antibodies were goat anti-
chicken 555 (1:500, Invitrogen, A11039), goat anti-mouse Alexa 488 (1:500; Invi-
trogen, A28175), and donkey anti-rabbit Alexa 594 (1:500; Invitrogen, A-21207).
Confocal images were taken on a Leica SPE Confocal Microscope. To quantify the
amount of labeling with different antibodies, we used high-resolution confocal z-
stacks to reconstruct the ventromedial ARC region in two coronal sections con-
taining the ME (bregma −1.7 and −2.0). For images capturing a wide area of the
MBH including the third ventricle, we used a ×20 ACS APO multi-immersion
objective (NA 0.6). For images taken at higher power to examine contacts between
GFAP- and Agrp-positive processes in the ARC, we used a ×63 ACS APO oil
immersion objective (NA 1.3). Imaris image analysis software version 9.1.0 (Bit-
plane) was then used to determine the volume of label-positive voxels (summation
of voxels with intensity levels above a fixed threshold designated as positive and
kept consistent across all images across all groups) throughout the region of
interest (ROI; i.e., ARC) and compared across study groups. For quantification of
GFAP–Agrp contacts, we determined the volume of co-labeled voxels expressing
both GFAP and Agrp at intensities above the threshold value in high-resolution
confocal stacks of the mediobasal ARC. While there are no cells that co-express
both of these markers, the co-labeling of individual voxels was used as a measure of
proximity between GFAP- and Agrp-expressing cell types.
Electron microscopy. Two cohorts of Lepob/ob mice were icv injected into the LV
with either hFGF1 or vehicle (pair-fed to the hFGF1-injected mice) as described
above. One cohort was sacrificed 5 days postinjection, and the second cohort was
sacrificed 28 days postinjection. Mice were anesthetized with ketamine and xylazine
and transcardially perfused with 0.1M PBS followed by 2% PFA and 2.5% glutar-
aldehyde in 0.1M PB (pH 7.4), following which the brains were post-fixed in the
same fixative overnight at 4 °C. The brains were then washed 6× with 0.1M PB at
4 °C, serially sectioned at 200 μm, and washed overnight in fresh 0.1M PB. Sections
were further post-fixed in 2% osmium tetroxide (Electron Microscopy Sciences) in
0.1M PB for 1 h at RT in the dark and washed 3× with cold d-H2O. Sections were
then dehydrated 1× in 25% ethanol, 1× in 50% ethanol, and 1 × 70% ethanol at 4 °C,
followed by an incubation in 2% uranyl acetate (Electron Microscopy Sciences) dis-
solved in 70% ethanol (Electron Microscopy Sciences) in the dark for 3 h at 4 °C.
Sections were then washed 1× in 70% ethanol, 3× in 95% ethanol, and 3× in 100%
ethanol, then washed 2× with propylene oxide at RT and embedded in Durcupan
(ACM; Fluka, Germany). Ultrathin sections (60–70 nm) were obtained with a dia-
mond knife in a UC7 ultramicrotome (Leica, Germany) and stained with lead citrate
(Reynolds’ solution)61. For pre-embedding NPY immunogold staining, mice were
fixed with 4% PFA in 0.1M PB (pH 7.4) as described above. Brain sections were
incubated with rabbit anti-NPY (1:1500, Abcam, ab30914) for 72 h at 4 °C and
incubated with gold-conjugated goat anti-rabbit antibody overnight followed by silver
enhancement62. MBH astrocyte coverage of synaptic boutons and synapses were then
imaged at 80 kV on a FEI Tecnai G2 Spirit transmission electron microscope (FEI
Europe, Netherlands) equipped with a Morada CCD digital camera (Olympus Soft
Image Solutions GmbH, Münster, Germany). Astrocyte coverage was determined by
quantitation of the synapse surface in contact with electron-lucent astroglial expan-
sions relative to the total perimeter of the synapse. For each synapse, the number of
DCVs and the total number of synaptic vesicles were quantified using Fiji’s (version
1.51j8) Cell Counter plugin63.
RNAScope. In a separate cohort of Lepob/ob mice, hFGF1 or vehicle (pair-fed to the
hFGF1-injected mice) was icv injected as described above. After 5 days, the mice
were anesthetized with ketamine and xylazine and transcardially perfused with
saline followed by fresh 10% neutral buffered formalin. Dissected brains were post-
fixed at RT for 8–12 h, then cut into 3 slabs, and further post-fixed for 16–32 h in
total. Slabs were followed by ethanol for 2–4 days and subsequently embedded in
paraffin. Sections were cut at 3–5 µm and single in situ hybridization (ISH) was
performed with the RNAscope® 2.5 VS Reagent Kit (catalog # 323250, Advanced
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Cell Diagnostics, Newark, CA) on a Ventana Discovery Ultra platform (Roche
Diagnostics, Penzberg, Germany). Pretreatment for ISH was 24 min target retrieval
and 16 min protease treatment. The probe applied targets mouse Gpr17 mRNA
(catalog # 318139), and signal was detected using the Fast Red Detection Kit
(catalog # 8127166001, Roche Diagnostics, Penzberg, Germany). For image ana-
lysis, the HALO ISH-IHC version 1.3 app (Indica Labs, Albuquerque, NM) was
used on two adjacent sections from the ARC region from each brain. In brief, the
area was drawn as an ROI on all images by an observer blinded to treatment
groups. Then all GPR17-positive cells were automatically detected and counted
using threshold settings for the HALO app that detected all positive cells in all
samples, with minimal background signal.
Relative gene expression (RT-PCR). Total RNA was extracted from hypothalami
using TRI Reagent (Sigma-Aldrich) and NucleoSpin RNA (Thermo Fisher Scien-
tific). Levels of hypothalamic transcripts were quantified by real-time PCR (ABI
Prism 7900HT; Applied Biosystems) using SYBR Green (Applied Biosystems), and
results were normalized to the housekeeping gene 18s. For comparative analysis,
RNA ratios of the treatment group were normalized to the icv Veh control group.
Other statistical analyses. Statistical analyses were performed using Prism 7 (Graph
Pad) and R (R Core Team, 2018. https://www.R-project.org/). Data are expressed as
dot plots representing data from individual animals or as mean ± SEM unless other-
wise indicated. Descriptive statistics and two-tailed t tests were computed in GraphPad
Prism 7 and probability values <0.05 were considered statistically significant. To assess
differences of BG across the 4 study groups over the entire 35-day treatment per-
iod shown in Fig. 6c, individual time series data for BG were summarized as the area
under the curve (AUC; units of (mg/dl) × days) using the trapezoidal rule. AUC data
were analyzed and adjusted for baseline BG using analysis of variance (ANOVA).
ANOVA was also used to assess BG on the final (35th) day of treatment. To speci-
fically assess the effect of time on group BG responses from Day 3 to Day 35 across the
four groups, the time series data in mg/dl were analyzed using the linear mixed model
approach. Repeated measurements were accounted for using subject-level random
intercepts and slopes64, while the fixed effects were group, time, the group × time
interaction, and baseline BG. Food intake was similarly analyzed both as AUC (using
ANOVA) and as a function of time (using mixed model analysis). Models were
adjusted for baseline food intake. For analyses performed in R, ANOVAs were per-
formed using the linear model (lm) procedure, mixed model analyses were performed
using the linear mixed-effects (lme4) procedure, and group contrasts were tested using
the generalized linear hypothesis test in the multcomp package.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All RNA-seq data generated in this study (snRNA-seq, scRNA-seq and bulk RNA-seq) are
available through the NCBI Gene Expression Omnibus (GEO) under Super Series
accession number GSE153551. This study also used publicly available datasets, including
“A Molecular Census of Arcuate Hypothalamus and Median Eminence Cell Types”
(GSE93374)16, “Single-cell RNA-seq of mouse hypothalamus” (GSE74672)17, “Single-cell
RNA-seq reveals hypothalamic cell diversity” (GSE87544)18, “Expression data from
reactive astrocytes purified from young adult mouse brains” (GSE35338)25, “RNA-seq
analysis of single cells of the oligodendrocyte lineage from nine distinct regions of the
anterior-posterior and dorsal-ventral axis of the mouse juvenile central nervous system”
(GSE75330)35, and “RNA-seq of mouse astrocytes in monoculture and co-cultured with
rat neurons (both inactive and active)” (E-MTAB-5514)31. The authors declare that all
the data supporting the findings of this study are available within the article and its
supplementary information files or from the corresponding authors upon request. Images
are available upon request from the corresponding authors. Source data are provided with
this paper.
Code availability
Codes are made available through https://perslab.github.io/bentsen-rausch-2020/.
Names, references, and version numbers of all software packages used are stated in the
“Methods” section.
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